NEW YORK (TheStreet) -- Shares of Valeant Pharmaceuticals Int'l (VRX) were rising in pre-market trading on Monday as the company announced that Paul Herendeen, an executive at animal healthcare company Zoetis (ZTS), will be its new CFO.

Herendeen replaces Robert Rosiello effective immediately. The move is the latest of several management changes at the beleaguered pharmaceutical company.

Rosiello will remain at Valeant as executive vice president of corporate development and strategy.

Herendeen has been the CFO of Zoetis since 2014.

Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.

The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: VRX